Document is current
Any future updates will be listed below
-
Authors
D’Ignazio, Emilio https://orcid.org/0000-0002-1033-9695
Sahin, Didem https://orcid.org/0000-0003-3558-5400
Baldi, Caterina https://orcid.org/0000-0002-3070-5568
Emery, Paul https://orcid.org/0000-0002-7429-8482
McGonagle, Dennis https://orcid.org/0000-0001-7715-8226
Wakefield, Richard https://orcid.org/0000-0001-5352-8683
Marzo-Ortega, Helena https://orcid.org/0000-0002-9683-3407
Zabotti, Alen https://orcid.org/0000-0002-0573-464X
Filippucci, Emilio https://orcid.org/0000-0002-7251-7784
Meridor, Katya https://orcid.org/0000-0001-5895-1974
Di Matteo, Andrea https://orcid.org/0000-0003-0867-7051
- License Information
-
More Information
Article History
Received: 28 January 2026
Accepted: 1 June 2026
First Online: 12 June 2026
Declarations
:
: CB has received speaking fees from Jannsen, Abbvie and Lilly. PE has received consulting fees from Abbvie, Activa, AstraZeneca, BMS, Boehringer Ingelheim, Galapagos, Gilead, Immunovant, Lilly, and Novartis. RJW has received speaker fees from Janssen and grant support from Abbvie. HM-O has received grant support from Janssen, Novartis, Pfizer and UCB. Honoraria and/or speaker fees from AbbVie, Advanz Pharma, Biogen, Eli-Lilly, Janssen, Moonlake, Novartis, Pfizer, Takeda, UCB and Zuellig-Pharma. AZ has received speaking fees from Amgen, Lilly, Novartis, J&J, Takeda, UCB, Alfasigma and research grant support from J&J. EF reports receiving speaking fees from AbbVie, IBSA, J&J, Novartis, and UCB. KM has received consultancy fees from AbbVie. ADM has received speaking fees from AstraZeneca and Janssen, and research grant support from Alfasigma.
